| abstract |
REFERS TO COMPOUNDS DERIVED FROM 4-INDOLYLSUFONAMIDES OF FORMULA IA, WHICH R1 IS NR8R9 OR A CYCLOALIPHATIC RADICAL; R2, R3, R5, R6 AND R7 ARE, INDEPENDENTLY OF IF, H, HALOGEN, NITRO, ALCOXY, CYANE, AMONG OTHERS; R4 IS H OR AN ALIPHATIC RADICAL; A IS A MONO OR POLYCYCLIC AROMATIC RING SYSTEM; N IS 0, 1, 2, 3 O 4; R8 AND R9 ARE, INDEPENDENTLY OR NOT AN ALIPHATIC RADICAL, AMONG OTHERS, WITH THE CONDITION THAT R8 AND R9 DO NOT REPRESENT H AT THE SAME TIME, AND IF ONE OF THEM, R8 OR R9, REPRESENTS AN ALIPHATIC RADICAL C1-C4, THE OTHER OF THEM REPRESENTS AN ALIPHATIC RADICAL WITH AT LEAST 5 CARBON ATOMS. PREFERRED COMPOUNDS ARE: N- [1- (2-DIMETHYLAMINOETHYL) -1H-INDOL-4-IL] -5-CHLORO-3-METHYLBENZO [B] THIOPHENE-2-SULPHONAMIDE; N- [1- (2-DIMETHYLAMINOETHYL) -1H-INDOL-4-IL] -NAPHTHALENE-2-SULFONAMIDE; N- [1- (2-DIMETHYLAMINOETHYL) -1H-INDOL-4-IL] -NAPHTHALENE-1-SULFONAMIDE; AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION OF THESE DERIVATIVES AND A MEDICINAL PRODUCT THAT CONTAINS THEM. THESE COMPOUNDS REGULATE THE SEROTONIN RECEPTOR (5-HT6) AND ARE USEFUL FOR THE TREATMENT OF DISORDERS RELATED TO THIS RECEPTOR SUCH AS OBESITY, CORONARY DISEASES, DIABETES |